

Appendix Table F62. Significant dose response effects of fesoterodine

Reference	Dose, mg/day	Outcome	Relative risk 95% CI)	Absolute risk difference 95%CI)	Number needed to treat (95% CI)	Attributable events/1000 treated (95% CI)
Chapple, 2007 ²⁵⁹	8 vs.4	Any adverse event	1.17 (1.00; 1.36)	0.084 (0.001; 0.166)	12 (6; 836)	84 (1; 166)
Nitti, 2007 ³⁵³	8 vs.4	Any adverse event	1.14 (1.01; 1.29)	0.088 (0.009; 0.166)	11 (6;112)	88 (9; 166)
Nitti, 2007 ³⁵³	8 vs.4	Dry eye	4.56 (1.00; 20.94)	0.025 (0.002; 0.048)	40 (21; 439)	25 (2; 48)
Chapple, 2007 ²⁵⁹	8 vs.4	Dry mouth	1.55 (1.18; 2.05)	0.120 (0.047; 0.193)	8 (5; 21)	120 (47; 193)
Nitti, 2007 ³⁵³	8 vs.4	Dry mouth	2.23 (1.63; 3.05)	0.196 (0.125; 0.266)	5 (4; 8)	196 (125; 266)
Chapple, 2007 ²⁵⁹	8 vs.4	Dry throat	7.56 (0.95; 60.01)	0.024 (0.004; 0.044)	41 (23; 263)	24 (4; 44)
Nitti, 2007 ³⁵³	8 vs.4	Hyper-tension	0.07 (0.00; 1.18)	-0.025 (-0.044; -0.005)	-40 (-184; -23)	-25 (-44; -5)
Chapple, 2007 ²⁵⁹	8 vs.4	Influenza	0.21 (0.05; 0.96)	-0.026 (-0.049; -0.003)	-38 (-354; -20)	-26 (-49; -3)
Nitti, 2007 ³⁵³	8 vs.4	Naso-pharyngitis	0.20 (0.04; 0.92)	-0.028 (-0.052; -0.004)	-36 (-223; -19)	-28 (-52; -4)
Sand, 2009 ³⁷²	8 vs.4	Dry mouth	1.67 (1.3; 42.09)	0.138 (0.080; 0.196)	7 (5; 13)	138 (80; 196)
Khullar, 2008 ³³⁰	4 vs.8	Dry mouth-total	0.54 (0.44; 0.67)	-0.159 (-0.209; -0.108)	-6 (-9; -5)	-159 (-209; -108)
Khullar, 2008 ³³⁰	4 vs.8	Lacrimal disorder	0.39 (0.17; 0.87)	-0.023 (-0.041; -0.004)	-44 (-239; -24)	-23 (-41; -4)
Khullar, 2008 ³³⁰	4 vs.8	Moderate dry mouth	0.31 (0.18; 0.53)	-0.065 (-0.093; -0.037)	-15 (-27 -11)	-65 (-93; -37)
Khullar, 2008 ³³⁰	4 vs.8	Mild dry mouth	0.68 (0.53; 0.87)	-0.071 (-0.116; -0.026)	-14 (-39 -9)	-71 (-116; -26)
Khullar, 2008 ³³⁰	4 vs.8	Naso-pharyngitis	2.63 (1.11; 6.24)	0.020 (0.003; 0.037)	50 (27;360)	20 (3; 37)
Khullar, 2008 ³³⁰	4 vs.8	Severe dry mouth	0.24 (0.08; 0.71)	-0.023 (-0.039; -0.007)	-44 (-141; -26)	-23 (-39; -7)
Sand, 2009 ³⁷²	8 vs.4	Treatment response	1.11 (1.00; 1.24)	0.065 (0.001; 0.130)	15 (8; 727)	65 (1; 130)